Hormone therapy (HRT) can provide meaningful relief from menopause symptoms, but every woman's experience is different. Two women with similar hot flashes, sleep disturbances or mood changes may respond differently to the same treatment.
Understanding why begins with the endocrine system, which regulates hormone production throughout the body. Genetics, body composition, lifestyle and overall health influence natural hormonal activity. During perimenopause and menopause, changing estrogen and progesterone levels add another layer of complexity.
The type of hormone therapy, dosage, delivery method and how the body absorbs and processes hormones can also affect treatment response. Researchers are exploring additional influences, including the gut microbiome, although their clinical significance remains uncertain.
Some women experience substantial symptom relief, while others have persistent symptoms or side effects. Understanding these differences helps healthcare practitioners personalize treatment, monitor progress and make adjustments as a woman's needs change.
What Factors Influence A Woman's Natural Hormonal Balance?
The endocrine system is a network of glands that produce and regulate hormones, including estrogen and progesterone. These hormones influence reproductive health and interact with many other body systems. During perimenopause, ovarian hormone production becomes more variable. After menopause, the ovaries essentially stop producing estrogen or progesterone. Endogenous estrogen shifts from ovarian estradiol to peripheral estrone converted from adipose tissue, thus changing the body's hormonal environment with the decline in both.
However, every woman's hormonal physiology is different. Several factors contribute to these differences:
Genetics: Inherited characteristics influence ovarian aging, reproductive lifespan and hormonal physiology.
Body composition: Estrogen plays a central role in regulating body fat distribution and white adipose tissue health. Adipose tissue (body fat) continues to produce estrogen after menopause, while muscle mass contributes to metabolic health.
Physical activity, energy availability and nutrition: Exercise supports metabolic health and good nutrition provides energy. For example, when a natural hormonal balance is interrupted by poor nutrition, even in menstruating female athletes, it may disrupt reproductive hormones.
Menopausal women are encouraged to consider maintaining muscle mass through resistance training.
Stress and sleep: Sleep disturbances are common during perimenopause and menopause. In the Maturitas (2024) researchers found an association between disrupted sleep architecture and higher cortisol levels, although self-reported insomnia and sleepiness were not associated with cortisol secretion.
Medical conditions: An individual’s health conditions such as thyroid disorders, metabolic conditions and certain medications may influence hormonal function as well.
Given these variable factors, it follows that hormonal balance is a dynamic physiological process rather than a fixed clinical target.
How Do Hormonal Changes During Perimenopause And Menopause Affect Treatment Needs?
Changing estrogen and progesterone levels during perimenopause and menopause influence symptoms and treatment needs. Reproductive stage helps guide decisions, but no single approach suits everyone.
Early perimenopause, late perimenopause and postmenopause
Early perimenopause may bring night sweats, sleep disruption or mood changes alongside ongoing periods. In late perimenopause (STRAW+10), ovulation becomes less predictable, menstrual gaps lengthen to 60 or more days of amenorrhea, and symptoms may intensify. Postmenopause begins after 12 consecutive months without menstruation, when there is no other explanation. These are useful clinical stages, but individual experiences do not follow a perfectly predictable timetable.
A woman with irregular periods and disruptive hot flashes may need a different discussion from someone several years beyond menopause who mainly experiences vaginal dryness or painful intercourse. Symptoms, contraception needs, bleeding patterns and the presence of a uterus can influence treatment choices. Systemic therapy may be considered for troublesome vasomotor symptoms, while local vaginal estrogen is an established option for genitourinary symptoms.
The "timing hypothesis" proposes that HRT initiated within 10 years of menopause onset or before age 60 may provide more benefit. International guidelines therefore generally favour initiating systemic HRT before age 60 or within 10 years of menopause onset when treatment is indicated.
What guides treatment considerations?
Treatment decisions consider symptoms, bleeding patterns, contraception needs, whether a woman has a uterus, and her medical history. Age and time since menopause are also important when assessing the benefits and risks of systemic HRT.
As symptoms, health and preferences change, treatment may need reassessment.
What Factors Determine How A Woman Responds To Hormone Therapy?
A woman's response to hormone therapy depends on the symptoms being treated, the hormone formulation, dosage, delivery method and how her body processes treatment. Systemic HRT is effective for bothersome hot flashes and night sweats, while low-dose vaginal estrogen treats many local vaginal and urinary symptoms. Benefits for fatigue, memory concerns or weight changes are less certain.
Formulation, dose and treatment goals
Estrogen formulation, dose and treatment schedule influence hormone exposure and tolerability. Women with a uterus who use systemic estrogen generally need progestogen to protect the uterine lining (endometrium). For breast-related concerns, micronized progesterone is generally preferred. The type and schedule of progestogen may also influence bleeding patterns and side effects.
Oral, transdermal and local vaginal treatment
Oral estrogen passes through the digestive system and undergoes first-pass metabolism in the liver. Transdermal patches, gels and sprays deliver estrogen through the skin, initially bypassing this process. These differences can influence safety considerations, including blood clot risk. Estrogen delivery can take several forms.
Low-dose vaginal estrogen acts mainly in local tissues, with much less systemic exposure than treatments intended for whole-body symptoms. The choice of delivery method depends on treatment goals and individual health considerations.
Absorption, estrogen metabolism and elimination
The body absorbs, metabolizes and eliminates estrogen through several pathways. Liver enzymes transform estrogen into metabolites that can leave through urine or bile. Some compounds may be modified in the intestine and reabsorbed, a process called enterohepatic recycling.
Absorption and hormone exposure can vary, making correct application and consistent use important. However, estrogen clearance or metabolite testing cannot reliably predict an individual's ideal HRT dose or symptom response.
The gut microbiome and other emerging explanations
Researchers are studying how the gut microbiome, including bacterial functions sometimes called the estrobolome, may influence estrogen metabolism and reabsorption.
Genetics, estrogen receptors and individual hormone sensitivity may also contribute to differences. However, these biological mechanisms are not yet reliable clinical predictors of HRT effectiveness or side effects. Treatment decisions continue to rely on symptoms, medical history, clinical assessment and response over time.
Why Do Women Experience Different Results And Side Effects From Hrt?
Women experience different results because their symptoms, treatment regimens and overall health vary. For example, HRT may relieve night sweats and improve sleep while daytime fatigue continues. This doesn't necessarily mean treatment has failed. Other health factors may contribute to persistent symptoms.
Results depend on the symptoms being treated
Systemic HRT is effective for hot flashes and night sweats, while local vaginal estrogen can relieve vaginal dryness and related urinary symptoms. Improvements in energy, memory or weight are less predictable. This helps women establish realistic treatment goals.
Some common side effects
Breast tenderness, bloating, fluid retention, nausea, headaches, mood changes and irregular bleeding may occur when starting or adjusting HRT. Dosage, hormone formulation and progestogen schedule can influence tolerability.
Although some bleeding changes occur during treatment adjustment, persistent, heavy or unexpected bleeding requires clinical assessment. More serious risks, including blood clots, stroke and breast cancer, depend on individual health factors and treatment characteristics and must be considered separately from symptom relief. Of note, with estrogen alone therapy breast cancer risk is little changed, whereas the small increase in risk is mainly with combined estrogen-progestogen.
Weight gain, weight loss and body composition
Weight changes around menopause are not necessarily caused by HRT. Aging and hormonal changes can influence fat distribution, particularly around the abdomen, while temporary fluid retention may affect weight without increasing body fat. Menopause itself is associated with changes in fat distribution.
Randomized research generally has not found substantial additional weight gain caused by menopausal HRT. Some studies suggest modest effects on body composition, but HRT is not an established weight-loss treatment. Nutrition, physical activity, sleep and metabolic health remain important.
Other reasons symptoms may continue
Sleep disorders, thyroid conditions, iron deficiency, medications and stress can contribute to symptoms that overlap with menopause. Persistent fatigue, low mood or poor sleep may require further assessment even when HRT is appropriately prescribed.
Reviewing these possibilities supports more informed care.
How Is Hormone Therapy Personalized And Monitored?
Hormone therapy is personalized according to a woman's menopause stage, symptoms, medical history, treatment goals and individual risks. A healthcare practitioner considers which symptoms are most disruptive, whether systemic or local treatment is appropriate, and any conditions that may affect treatment safety. Hormone therapy is personalized through a clinical assessment.
Choosing treatment and reviewing progress
Treatment selection includes hormone formulation, dosage, delivery method and endometrial protection when required. Follow-up evaluates symptom relief alongside side effects, bleeding changes and overall tolerability. The clinician considers estrogen formulation, dose and delivery route.
If treatment is not providing the expected benefits, the practitioner may review medication use, adjust the regimen or investigate other possible causes. Treatment needs can also change as a woman's health and circumstances evolve.
When hormone tests help, and when they do not
Routine hormone blood tests are generally not useful for determining the ideal menopausal HRT dose. Hormone levels fluctuate during perimenopause, and laboratory results do not reliably predict symptom improvement. Testing may still help investigate specific medical concerns.
Preparing for a conversation with your nurse practitioner
Keeping a brief record of symptoms, improvements, side effects and bleeding changes can make follow-up more productive. Sharing this information with your Rosie nurse practitioner helps guide decisions about treatment adjustments and ongoing care.
Understanding Your Individual HRT Experience
Every woman's experience with hormone therapy is different. Menopause stage, individual health, symptoms and treatment choices all influence the results, while research continues to explore other factors.
Finding the right approach means balancing symptom relief, safety and tolerability. As your needs change, working with your Rosie nurse practitioner can help ensure your treatment continues to support your health and well-being.
This article is general educational information and does not replace individualized medical advice.
Frequently Asked Questions
Why does HRT work for my friend but not the same way for me?
Your symptoms, menopause stage, health history and prescription differ. A clinician can review which treatment goals have improved and what else may be contributing.
Can HRT help hot flashes but leave fatigue unchanged?
Systemic HRT can relieve vasomotor symptoms, while fatigue may also reflect sleep disorders, thyroid problems, iron deficiency or other causes.
Does the type of estrogen affect side effects?
Formulation, dose, delivery route and progestogen regimen can influence exposure and tolerability. The best choice depends on your clinical circumstances. For women with a uterus using systemic estrogen, a progestogen, such as micronized progesterone, is still needed for endometrial protection regardless of the estrogen delivery route.
Does HRT usually cause weight gain?
Controlled research generally has not found substantial extra weight gain caused by menopausal HRT. Menopause, aging, fluid retention and other factors can affect weight.
Can blood tests or microbiome tests predict my ideal HRT dose?
Routine hormone levels and microbiome profiles do not reliably identify an ideal dose or predict symptom relief. Your symptoms and clinical assessment guide treatment.
Sources
De Souza MJ, Williams NI, Misra M, Nattiv A, Joy E, Barrack M, Ricker EA, Gorrell S, Koltun KJ, O'Donnell E, Mallinson RJ, Salamunes ACC, Woodruff K, Fredericson M, Plessow F. Update to the Female Athlete Triad Coalition Consensus Statement, Sports Med. 2025.
https://pubmed.ncbi.nlm.nih.gov/41474493/
González-Gálvez N, Moreno-Torres JM, Vaquero-Cristóbal R. Resistance training effects on healthy postmenopausal women, 2024. https://pubmed.ncbi.nlm.nih.gov/38353251/
Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ; STRAW 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10. Menopause. 2012.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3340903/
International Menopause Society. International Menopause Society recommendations and key messages on women’s midlife health and menopause. Climacteric. 2025. https://doi.org/10.1080/13697137.2025.2585487
Khalifey HT, Mahereen R, Adwan R, Chahine R, Kaidali M, Mirza SF, Tullah SN, Shaikh S, Hammad S, Sukkarieh HH. The impact of hormone replacement therapy on cardiovascular health in postmenopausal women: a narrative review. Front Reproductive Health. 2026.
https://pubmed.ncbi.nlm.nih.gov/41660151/
Kim J, Munster P. Estrogens and breast cancer. Annals of Oncology. 2025 Lim MJS et al. Diet, the Gut Microbiome, and Estrogen Physiology: A Review in Menopausal Health and Interventions. Nutrients. 2026. https://pubmed.ncbi.nlm.nih.gov/41978103/
Lumsden MA et al. European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. European Journal of Endocrinology. 2025. https://academic.oup.com/ejendo/article/193/4/G49/8281862
Primary Care Alberta and Alberta Health Services. Perimenopause and Menopause Pathway: Review your treatment and management options. 2026. https://myhealth.alberta.ca/perimenopause-menopause-pathway/review-your-treatment-and-management-options
Primary Care Alberta and Alberta Health Services. Perimenopause and Menopause Pathway: Start your treatment or management and watch your symptoms. 2026. https://myhealth.alberta.ca/perimenopause-menopause-pathway/start-your-treatment-or-management-and-watch-your-symptoms
Saravinovska K et al. The impact of estrogen status on the gut microbiome: a systematic review and meta-analysis. Frontiers in Endocrinology. 2026. https://pubmed.ncbi.nlm.nih.gov/42006274/
Stanczyk FZ. Metabolism of endogenous and exogenous estrogens in women. Journal of Steroid Biochemistry and Molecular Biology. 2024. https://pubmed.ncbi.nlm.nih.gov/38692334/
Stankovic, S., Shekari, S., Huang, Q.Q. et al. Genetic links between ovarian ageing, cancer risk and de novo mutation rates. Nature. 2024.
https://www.nature.com/articles/s41586-024-07931-x
Sahola Nima, Toffol Elena, Kalleinen Nea, Polo-Kantola Päivi. Worse sleep architecture but not self-reported insomnia and sleepiness is associated with higher cortisol levels in menopausal women. Maturitas, Volume 187, 2024
https://doi.org/10.1016/j.maturitas.2024.108053
Troìa L, Garassino M, Volpicelli AI, Fornara A, Libretti A, Surico D, Remorgida V. Sleep Disturbance and Perimenopause: A Narrative Review. J Clin Med. 2025
https://pmc.ncbi.nlm.nih.gov/articles/PMC11901009/
Younglove, Courtney. Menopause hormone therapy in weight management, Obes Pillars, 2026.
https://pmc.ncbi.nlm.nih.gov/articles/PMC13010941/